RPRX

Royalty Pharma Plc

RPRX, USA

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

https://www.royaltypharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.22

Next Payout:

Dec 10, 2025

Yield:

2.2923 %
RPRX
stock
RPRX

Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX MarketBeat

Read more →
RPRX
stock
RPRX

Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$45.9844

Analyst Picks

Strong Buy

4

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

22.72

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

3.35

Low 1

High 3

Return on Equity (ROE)

-

Very Low

4.49 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.49 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

104.80 %

Low 5%

High 15%

Debt to Equity

-

Very Low

1.52

Low 1

High 0.3

Investors

* Institutions hold a combined 84.81% of the total shares of Royalty Pharma Plc

1.

Morgan Stanley - Brokerage Accounts

(10.7807%)

since

2025/06/30

2.

FMR Inc

(9.3358%)

since

2025/06/30

3.

Vanguard Group Inc

(8.4151%)

since

2025/06/30

4.

BlackRock Inc

(5.8823%)

since

2025/06/30

5.

Capital Research & Mgmt Co - Division 3

(5.0615%)

since

2025/06/30

6.

Baillie Gifford & Co Limited.

(4.1686%)

since

2025/06/30

7.

Swedbank AB

(2.8123%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.6029%)

since

2025/07/31

9.

State Street Corp

(2.3583%)

since

2025/06/30

10.

Geode Capital Management, LLC

(1.8914%)

since

2025/06/30

11.

Vanguard Mid Cap Index Institutional

(1.8483%)

since

2025/07/31

12.

American Funds New Perspective A

(1.6369%)

since

2025/06/30

13.

Capital Group New Perspective Comp

(1.6369%)

since

2025/06/30

14.

Caledonia (Private) Investments Pty Ltd

(1.4908%)

since

2025/06/30

15.

Adage Capital Partners Gp LLC

(1.3879%)

since

2025/06/30

16.

Morgan Stanley Growth

(1.3752%)

since

2025/06/30

17.

Morgan Stanley Inst Growth I

(1.3752%)

since

2025/06/30

18.

Morgan Stanley Growth SMA

(1.3752%)

since

2025/06/30

19.

MS INVF US Advantage I

(1.2506%)

since

2025/07/31

20.

NORGES BANK

(1.1646%)

since

2025/06/30

21.

MS INVF US Growth I

(1.0612%)

since

2025/07/31

22.

Victory Capital Management Inc.

(1.039%)

since

2025/06/30

23.

Capital Group Growth Fnd of Amer Comp

(1.0145%)

since

2025/06/30

24.

American Funds Growth Fund of Amer A

(1.0145%)

since

2025/06/30

25.

Swedbank Robur Aktiefond Pension

(0.9464%)

since

2025/07/31

26.

Fidelity Advisor Equity Growth I

(0.9451%)

since

2025/07/31

27.

UBS Asset Mgmt Americas Inc

(0.9431%)

since

2025/06/30

28.

Northern Trust Corp

(0.9304%)

since

2025/06/30

29.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9013%)

since

2025/07/31

30.

Swedbank Robur Transfer 70

(0.8549%)

since

2025/07/31

31.

Fidelity VIP Growth Initial

(0.8379%)

since

2025/07/31

32.

VictoryShares Free Cash Flow ETF

(0.8326%)

since

2025/08/29

33.

Strategic Advisers Fidelity US TtlStk

(0.8324%)

since

2025/07/31

34.

Vanguard Value Index Inv

(0.7339%)

since

2025/07/31

35.

Charles Schwab Investment Management Inc

(0.696%)

since

2025/06/30

36.

Patients Capital Management LLC

(0.6912%)

since

2025/06/30

37.

Arrowstreet Capital Limited Partnership

(0.6885%)

since

2025/06/30

38.

American Funds American Balanced A

(0.6863%)

since

2025/06/30

39.

Newsouth Capital Management Inc

(0.6677%)

since

2025/06/30

40.

Amundi

(0.6471%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.31

Latest Release

Date

2025-09-30

EPS Actual

1.17

EPS Estimate

1.04

EPS Difference

0.13

Surprise Percent

12.5%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(6)
Growth
Moderate Growth(5.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.